For a variety of economic reasons, biotech has not participated in the current tech rally. And, as a result, there has likely never been a wider gap between tech stocks and biotech stocks. Right now, as we report in this week’s issue, a major biotech bull market is forming.
This week we report on a one-time railroad company that has become one of the greatest success stories in American finance – finding capital efficient ways to generate new revenue and maintaining 60% profit margins for decades.
Today we’re discussing how rate cuts and consumer weakness play out in the markets, what might happen, and how to prepare. What follows are hard-earned, actionable insights from Porter Stansberry, based on his 25 years of navigating markets.
Shares of America’s largest insurer soared in August after a strong earnings report, Warren Buffett bought into one Big Secret portfolio company, and a beverage company continues to show promise despite months of struggling to increase sales.
As low-cost EV manufacturers lead the transition to electrified transport, and with lithium (the key component of electric vehicle batteries) prices down 85% in the last three years, the lithium mining industry has become one of the most beaten down in the stock market. That has created the ultimate contrarian opportunity we introduce in this issue.
